After clicking on a story, use the back arrow in your browser to return to your search results. Use phrases "in quotes" or the tools below to better filter your results.
Working to move beyond its core business of cystic fibrosis treatments, Vertex recently gained approval for Casgevy, a gene editing therapy for sickle cell disease and beta thalassemia.
The private capital firm will invest in a range of intellectual property assets across pharmaceuticals, entertainment, energy transition, sports and brands.
March 18, 2024
Join our Membership
Join the Merger & Acquisitions community to access premium content and exclusive member-only benefits.